Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Orphatec Pharmaceuticals GmbH

Latest From Orphatec Pharmaceuticals GmbH

The Orphan Drug Boom: Gold Rush Or Flash In The Pan?

Rare disease drug development has ballooned in just three years, powered by the success of independent biotechs like Alexion, Big Pharma’s entrée into the field, and pressure from regulators and payors that is dis-incentivizing development of traditional primary care drugs. The positive momentum has intensified dealmaking in the orphan drug space and is giving investors confidence to back rare disease-focused start-ups. Some have coined the resulting movement the “orphan drug bubble,” but interest isn’t likely to deflate soon – at least not as long as Big Pharma continues to invest in the area and industry is able to sustain a favorable reimbursement climate for ultra-premium-priced drugs.

BioPharmaceutical

Deals Shaping the Medical Industry (2/2012)

The Dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.

Medical Device BioPharmaceutical

With Trio Of 2011 Deals, Alexion Looks To Nearly Double R&D Spending In 2012

The biotech, which is enjoying growing sales of high-priced, ultra-orphan terminal complement inhibitor Soliris, also has a pipeline of four other clinical and preclinical candidates for rare diseases.

BioPharmaceutical Clinical Trials

Alexion Pumps Up Its Rare Disease Portfolio With Enobia Acquisition

Alexion could pay as much as $1.08 billion for access to Enobia's mid-stage rare disease compound asfotase alpha.

BioPharmaceutical United States
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Metabolic Disorders
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Germany
  • Parent & Subsidiaries
  • Orphatec Pharmaceuticals GmbH
  • Senior Management
  • Contact Info
  • Orphatec Pharmaceuticals GmbH
    Cologne,
    Germany
Advertisement
Advertisement
UsernamePublicRestriction

Register